title: Cardiac disease after radiation therapy for Hodgkin's disease: analysis of 48 patients.
abstract: Occult or overt but delayed cardiac disease after thoracic radiotherapy for Hodgkin's disease may be common. Detailed cardiac evaluations were performed in 48 patients with Hodgkin's disease at risk a mean of 97 months after radiotherapy. The study protocol included echocardiography, gated radionuclide ventriculography, and cardiac catheterization. Cardiac disease was found in 46 patients (96%) and included constrictive or occult constrictive pericarditis (24 patients), an abnormal hemodynamic response to a fluid challenge (14 patients), coronary artery disease (6 patients), and left ventricular dysfunction (2 patients). Most patients (53%) had normal echocardiograms. Gated blood pool radionuclide angiocardiography was performed in 42 patients. Excluding patients with occlusive coronary artery disease, the left ventricular ejection fraction at rest (mean 59%) and during exercise (mean 69%) was within normal limits. Congestive heart failure occurred in 2 patients. Six patients had pericardiectomy for constrictive pericarditis and 3 patients had coronary artery bypass surgery for coronary artery disease. Thus (1) delayed cardiac disease after radiotherapy is common, (2) chronic pericardial disorders are the most frequent manifestations of this disease, and (3) the prognosis for patients who have radiation-induced cardiac disease is generally favorable.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D006328:Cardiac Catheterization; D002648:Child; D003327:Coronary Disease / Q000209:etiology; D004452:Echocardiography; D005500:Follow-Up Studies; D006321:Heart / Q000528:radiation effects; D006331:Heart Diseases / Q000175:diagnosis / Q000209:etiology*; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006689:Hodgkin Disease / Q000532:radiotherapy*; D006801:Humans; D008875:Middle Aged; D010494:Pericarditis, Constrictive / Q000209:etiology; D011877:Radionuclide Imaging; D011878:Radiotherapy / Q000009:adverse effects*